



PATENT Attorney Docket No. 056291-5283

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: HENNEQUIN et al.	) Confirmation No.: 3653
Application No.: 10/578,663	) Group Art Unit: <b>1624</b>
Filed: January 17, 2007	) Examiner: TRUONG
For: QUINAZOLINE DERIVATIVES	) Date: January 28, 2008

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants request the Examiner to consider this Supplemental Information Disclosure Statement and the documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application. Accordingly, Applicants do not believe a fee is due for filing this Supplemental Information Disclosure Statement.

With the exception of U.S. Patents and Publications, copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." Applicants reserve the right to take appropriate action to establish the patentability of the disclosed

Attorney Docket No.: 056291-5283 Application No. 10/578,663

Page 2

invention over the listed documents, should one or more of the documents be applied against the claims of

the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by

this paper to charge any additional fees during the entire pendency of this application including fees due

under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or

credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a

CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R.

§1.136(a)(3).

Respectfully Submitted

Morgan Lewis & Bockius

Date:

January 28, 2008

Morgan Lewis & Bockius LLP

Customer No. 09629

1111 Pennsylvania Avenue, N.W.

Washington, D.C. 20004

Tel. No.: 202-739-3000

By:

Donald J. Bird

Registration No. 25,323

Tel. No.: (202) 739-5320

Fax No.: (202) 739-3001